Sava Infond d.o.o. Makes New $633,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Sava Infond d.o.o. purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, HoldingsChannel reports. The firm purchased 4,000 shares of the medical research company’s stock, valued at approximately $633,000.

A number of other institutional investors have also made changes to their positions in the business. Blue Trust Inc. grew its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. raised its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after buying an additional 332 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Price Performance

NTRA opened at $149.84 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market capitalization of $20.26 billion, a P/E ratio of -85.14 and a beta of 1.80. The company’s 50 day simple moving average is $160.29 and its 200-day simple moving average is $150.55. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 43,502 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the transaction, the chief financial officer now owns 70,629 shares of the company’s stock, valued at $12,492,857.52. This represents a 38.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 306,797 shares of company stock worth $48,940,883 over the last three months. 7.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NTRA. Royal Bank of Canada started coverage on Natera in a research report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price objective for the company. Morgan Stanley raised their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Sanford C. Bernstein increased their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Finally, The Goldman Sachs Group lifted their target price on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.